SLIDE 1
2
Company & Employees
- Founded 6 years ago
- Located in Massachusetts
- 31 employees
- Experienced leadership
Overview for the New York Pharma Forum November 12, 2012 Company - - PowerPoint PPT Presentation
Overview for the New York Pharma Forum November 12, 2012 Company - - PowerPoint PPT Presentation
Overview for the New York Pharma Forum November 12, 2012 Company & Employees Founded 6 years ago Located in Massachusetts 31 employees Experienced leadership Collectively more than 200 years of device development experience
SLIDE 2
SLIDE 3
3
- Duke Collier, CEO
- Blaine McKee, Ph.D., Executive VP, CBO
- Maria Palasis, Ph.D., Executive VP, CTO
- Raymond Knox, VP Operations
- Wendy Naimark, Ph.D., Director R&D
480 Biomedical’s Management Team
SLIDE 4
4
- Carmichael Roberts, Ph.D., Chairman
- Duke Collier, CEO
- George Whitesides, Ph.D., Harvard University
- Bob Langer, Sc.D., MIT
- Terry McGuire, Polaris Venture Partners
- Jimmy Rosen, Intersouth Partners
- Guido Neels, former Guidant COO
- Tony Semedo, Medtronic
Investors: Polaris, North Bridge, Intersouth, and Medtronic
480 Biomedical’s Board
SLIDE 5
5
480 Biomedical’s Lead Product: A Transformational Bioresorbable Scaffold
SLIDE 6
6
WW SFA Disease Prevalence >12MM
Source: DataMonitor Pipeline Perspectives: PAD 2007; internal estimates
8.5M PAD 4.7M SFA 9.5M PAD 4.9M SFA 5.5M PAD 2.8M SFA
SLIDE 7
7
- Abandoning coronary
stents, but investing in peripheral interventions
- Acquired DEB
company Lutonix in Dec 2011 for $225M + $100M earnouts
- Acquired EV3 in
July 2010 for $2.6B, strong peripheral portfolio
Major Players are Active in the Space
- Developing an SFA
bioresorbable scaffold
- Purchased Invatec in April
2010 for $350M plus $150M in earnouts, has leading DEB for periphery
SLIDE 8
8
Current SFA Treatments are Suboptimal
Lower Higher Lower Higher
Effectiveness Invasiveness
Surgical Bypass Balloon Angioplasty Medical Management Stents
SFA Treatment Landscape
Atherectomy
SLIDE 9
9
- Strong
– Scaffolds the vessel during healing
- Flexible
– Responds to vessel motion
- Bioresorbable
– There only while its needed – Safely resorbed by the body
Attributes of the the Optimal SFA Stent
SLIDE 10
10
Bioresorbable Scaffolds are Optimal for SFA
Drug-Eluting Balloon Drug-Eluting Stent Bioresorbable Scaffold
Ease of Procedure
✓ ✓ ✓
Supports vessel during healing
✓ ✓
No Permanent Implant
✓ ✓
SLIDE 11
11
StanzaTM: A Superior Bioresorbable
Device Image Strength Flexibility Absorption Time ABSORBTM
Abbott Vascular Similar to metal stents Highly rigid 3-4 years
IGAKI-TAMAI
Kyoto Medical Planning Low radial strength Semi-rigid 3-4 years
StanzaTM
480 Biomedical Similar to metal stents Highly flexible Elongates with vessel ~1 year =most desirable =least desirable
SLIDE 12
12
STANCE Trial A Safety Assessment
- f the StanzaTM Self-
Expanding Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
SLIDE 13
13
StanzaTM Scaffold Supports Drug Delivery
No Drug Drug-Eluting
Drug-eluting scaffold in advanced preclinical testing
SLIDE 14
14
StanzaTM Can be Used to Treat Other Vessels and Lumens in the Body
Below the Knee Coronary
Other Arteries
Sinus Airway GI
SLIDE 15